000169697 001__ 169697
000169697 005__ 20240303004806.0
000169697 0247_ $$2doi$$a10.3390/cancers13123010
000169697 0247_ $$2pmid$$apmid:34208476
000169697 0247_ $$2altmetric$$aaltmetric:136044231
000169697 037__ $$aDKFZ-2021-01504
000169697 041__ $$aEnglish
000169697 082__ $$a610
000169697 1001_ $$0P:(DE-He78)9d0264be3c1caadf9a94dcd1cb8b4f53$$aHibbert, Julia$$b0$$eFirst author$$udkfz
000169697 245__ $$aSensitivity and Specificity of Human Papillomavirus (HPV) 16 Early Antigen Serology for HPV-Driven Oropharyngeal Cancer: A Systematic Literature Review and Meta-Analysis.
000169697 260__ $$aBasel$$bMDPI$$c2021
000169697 3367_ $$2DRIVER$$aarticle
000169697 3367_ $$2DataCite$$aOutput Types/Journal article
000169697 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1635318909_25420$$xReview Article
000169697 3367_ $$2BibTeX$$aARTICLE
000169697 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169697 3367_ $$00$$2EndNote$$aJournal Article
000169697 500__ $$a#EA:F022#LA:F022#
000169697 520__ $$aAntibodies against HPV16 early proteins have been shown to be promising biomarkers for the identification of HPV-driven oropharyngeal cancer (HPV-OPC) among OPC cases in multiple studies. A systematic literature search was performed to identify original research articles comparing HPV early antigen serology with established reference methods to determine molecular HPV tumor status. Random-effects models were used to calculate summary estimates for sensitivity and specificity of HPV16 E2, E6 and E7 serology for HPV-OPC. Subgroup analyses were performed to explore heterogeneity across studies and describe variables associated with test performance. We identified n = 23 studies meeting all eligibility criteria and included these in the meta-analysis. E6 serology showed the best performance with pooled sensitivity and specificity estimates of 83.1% (95% confidence interval (CI) 72.5-90.2%) and 94.6% (95% CI 89.0-97.4%), respectively, while E2 and E7 serological assays were highly specific (E2: 92.5% (95% CI 79.1-97.6%); E7: 88.5% (95% CI 77.9-94.4%)) but moderately sensitive (E2: 67.8% (95% CI 58.9-75.6%); E7: 67.0% (95% CI 63.2-70.6%)). Subgroup analyses revealed increased pooled sensitivity for bacterially (89.9% (95% CI 84.5-93.6%)) vs. in vitro expressed E6 antigen (55.3% (95% CI 41.0-68.7%)), while both showed high specificity (95.2% (95% CI 93.0-96.7%) and 91.1% (95% CI 46.6-99.2%), respectively). Pooled specificity estimates for HPV16 E2, E6 and E7 serology were significantly lower in studies utilizing HPV DNA PCR as the only molecular reference method compared to those using a combination of any two reference methods (HPV DNA, RNA, in situ hybridization (ISH), p16 immunohistochemistry (IHC)), or histopathological reference methods (ISH or p16 IHC) as stand-alone marker. In conclusion, HPV16 E6 seropositivity is a highly sensitive and specific biomarker for HPV-OPC. However, its performance differs between serological assays and depends on molecular reference methods.
000169697 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000169697 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169697 650_7 $$2Other$$aHPV
000169697 650_7 $$2Other$$aantibodies
000169697 650_7 $$2Other$$ameta-analysis
000169697 650_7 $$2Other$$aoropharyngeal cancer
000169697 650_7 $$2Other$$asensitivity
000169697 650_7 $$2Other$$aserology
000169697 650_7 $$2Other$$aspecificity
000169697 650_7 $$2Other$$asystematic review
000169697 7001_ $$0P:(DE-He78)94cc2690204e1d82d8ca318b17cd2e65$$aHalec, Gordana$$b1$$udkfz
000169697 7001_ $$aBaaken, Dan$$b2
000169697 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b3$$udkfz
000169697 7001_ $$0P:(DE-He78)b1326dc42cbbc5f92b10fe5f254f0bc2$$aBrenner, Nicole$$b4$$eLast author$$udkfz
000169697 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers13123010$$gVol. 13, no. 12, p. 3010 -$$n12$$p3010$$tCancers$$v13$$x2072-6694$$y2021
000169697 909CO $$ooai:inrepo02.dkfz.de:169697$$pVDB
000169697 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9d0264be3c1caadf9a94dcd1cb8b4f53$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000169697 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)94cc2690204e1d82d8ca318b17cd2e65$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000169697 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000169697 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b1326dc42cbbc5f92b10fe5f254f0bc2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000169697 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000169697 9130_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000169697 9141_ $$y2021
000169697 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2019$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-04
000169697 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2019$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000169697 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000169697 9201_ $$0I:(DE-He78)F022-20160331$$kF022$$lInfektionen und Krebs-Epidemiologie$$x0
000169697 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x1
000169697 980__ $$ajournal
000169697 980__ $$aVDB
000169697 980__ $$aI:(DE-He78)F022-20160331
000169697 980__ $$aI:(DE-He78)F020-20160331
000169697 980__ $$aUNRESTRICTED